Driss Ait Ouakrim

Driss Ait Ouakrim

Auto-generated profile, based on publicly available information

Driss Ait Ouakrim

Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia

Research Focus & Metrics

Representative Publications

View All Publications
1 January 2019 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
ACAlessandro Cassini
Alessandro Cassini
LHLiselotte Diaz Högberg
Liselotte Diaz Högberg
DPDiamantis Plachouras
Diamantis Plachouras
AQAnnalisa Quattrocchi
Annalisa Quattrocchi
AHAna Hoxha
Ana Hoxha
SHSusan Hopkins
Susan Hopkins
Infections due to antibiotic-resistant bacteria are threatening modern health care. However, estimating their incidence, complications, and attributable mortality is challenging. We aimed to estimate the burden of infections caused by antibiotic-resistant bacteria of public health concern in countries of the EU and European Economic Area (EEA) in 2015, measured in number of cases, attributable deaths, and disability-adjusted life-years (DALYs). We estimated the incidence of infections with 16 antibiotic resistance-bacterium combinations from European Antimicrobial Resistance Surveillance Network (EARS-Net) 2015 data that was country-corrected for population coverage. We multiplied the number of bloodstream infections (BSIs) by a conversion factor derived from the European Centre for Disease Prevention and Control point prevalence survey of health-care-associated infections in European acute care hospitals in 2011-12 to estimate the number of non-BSIs. We developed disease outcome models for five types of infection on the basis of systematic reviews of the literature. From EARS-Net data collected between Jan 1, 2015, and Dec 31, 2015, we estimated 671 689 (95% uncertainty interval [UI] 583 148-763 966) infections with antibiotic-resistant bacteria, of which 63·5% (426 277 of 671 689) were associated with health care. These infections accounted for an estimated 33 110 (28 480-38 430) attributable deaths and 874 541 (768 837-989 068) DALYs. The burden for the EU and EEA was highest in infants (aged <1 year) and people aged 65 years or older, had increased since 2007, and was highest in Italy and Greece. Our results present the health burden of five types of infection with antibiotic-resistant bacteria expressed, for the first time, in DALYs. The estimated burden of infections with antibiotic-resistant bacteria in the EU and EEA is substantial compared with that of other infectious diseases, and has increased since 2007. Our burden estimates provide useful information for public health decision-makers prioritising interventions for infectious diseases. European Centre for Disease Prevention and Control.

7 September 2011 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
ASAnthony Scott
Anthony Scott
PSPeter Sivey
Peter Sivey
DODriss Ait Ouakrim
Driss Ait Ouakrim
LWLisa Willenberg
Lisa Willenberg
LNLucio Naccarella
Lucio Naccarella
DYDoris Young
Doris Young

6 October 2015 in BMJ
Verified
Journal Article
Open access
PDF file
DODriss Ait Ouakrim
Driss Ait Ouakrim
CPCécile Pizot
Cécile Pizot
MBMagali Boniol
Magali Boniol
Matteo MalvezziMatteo Malvezzi
Matteo Malvezzi
MBMathieu Boniol
Mathieu Boniol
PAPhilippe Autier
Philippe Autier
Objective To examine changes in colorectal cancer mortality in 34 European countries between 1970 and 2011. Design Retrospective trend analysis. Data source World Health Organization mortality database. Population Deaths from colorectal cancer between 1970 and 2011. Profound changes in screening and treatment efficiency took place after 1988; therefore, particular attention was paid to the evolution of colorectal cancer mortality in the subsequent period. Main outcomes measures Time trends in rates of colorectal cancer mortality, using joinpoint regression analysis. Rates were age adjusted using the standard European population. Results From 1989 to 2011, colorectal cancer mortality increased by a median of 6.0% for men and decreased by a median of 14.7% for women in the 34 European countries. Reductions in colorectal cancer mortality of more than 25% in men and 30% in women occurred in Austria, Switzerland, Germany, the United Kingdom, Belgium, the Czech Republic, Luxembourg, and Ireland. By contrast, mortality rates fell by less than 17% in the Netherlands and Sweden for both sexes. Over the same period, smaller or no declines occurred in most central European countries. Substantial mortality increases occurred in Croatia, the former Yugoslav republic of Macedonia, and Romania for both sexes and in most eastern European countries for men. In countries with decreasing mortality, reductions were more important for women of all ages and men younger than 65 years. In the 27 European Union member states, colorectal cancer mortality fell by 13.0% in men and 27.0% in women, compared with corresponding reductions of 39.8% and 38.8% in the United States. Conclusion Over the past 40 years, there has been considerable disparity in the level of colorectal cancer mortality between European countries, as well as between men and women and age categories. Countries with the largest reductions in colorectal cancer mortality are characterised by better accessibility to screening services, especially endoscopic screening, and specialised care.

7 July 2015 in JAMA
Verified
Journal Article
Open access
PDF file
SDSeyedeh Ghazaleh Dashti
Seyedeh Ghazaleh Dashti
RCRowena Chau
Rowena Chau
DODriss Ait Ouakrim
Driss Ait Ouakrim
DBDaniel Buchanan
Daniel Buchanan
MCMark Clendenning
Mark Clendenning
AWAung Win
Aung Win
Endometrial cancer is the most common type of gynecologic cancer in developed countries.1,2 Between 2% and 5% of all endometrial cancer cases are associated with a hereditary susceptibility to cancer, mainly Lynch syndrome,3 which is an autosomal dominant disorder caused by a germline mutation in one of the DNA mismatch repair (MMR) genes MLH1 (RefSeq NM_000249), MSH2 (RefSeq NM_000251), MSH6 (RefSeq NM_000179), PMS2 (RefSeq NM_000535), and EPCAM (RefSeq NM_000535).4 Although estimates vary, the incidence of Lynch syndrome may be as high as 1 in 370 in the general population in the United States.5 Depending on the mutated gene, cumulative risk of developing endometrial cancer by age 70 years for women is thought to be between 15% and 30%.6-8 Apart from hysterectomy, there is no consensus recommendation for reducing endometrial cancer risk for women with an MMR gene mutation.9,10

24 June 2015 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
DODriss Ait Ouakrim
Driss Ait Ouakrim
SDSeyedeh Ghazaleh Dashti
Seyedeh Ghazaleh Dashti
RCRowena Chau
Rowena Chau
DBDaniel Buchanan
Daniel Buchanan
MCMark Clendenning
Mark Clendenning
AWAung Win
Aung Win
Inheritance of a germline mutation in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 causes a high risk of colorectal and other cancers (Lynch Syndrome). Use of aspirin has been shown to be associated with a reduced risk of colorectal cancer for the general population as well as for MMR gene mutation carriers. The aim of this study was to determine whether use of aspirin and ibuprofen in a nontrial setting is associated with the risk of colorectal cancer risk for MMR gene mutation carriers. We included 1858 participants in the Colon Cancer Family Registry who had been found to have a pathogenic germline mutation in a MMR gene (carriers). We used weighted Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. A total of 714 carriers (38%) were diagnosed with colorectal cancer at a mean age of 42.4 (standard deviation 10.6) years. A reduced risk of colorectal cancer was associated with aspirin use (for 1 month to 4.9 years: HR = 0.49, 95% CI = 0.27 to 0.90, P = .02; for ≥5 years: HR = 0.25, 95% CI = 0.10 to 0.62, P = .003) and ibuprofen use (for 1 month to 4.9 years: HR = 0.38, 95% CI = 0.18 to 0.79, P = .009; for ≥5 years: HR = 0.26, 95% CI = 0.10 to 0.69, P = .007), compared with less than one month of use. Our results provide additional evidence that, for MMR gene mutation carriers, use of aspirin and ibuprofen might be effective in reducing their high risk of colorectal cancer.

6 June 2016 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
DBDaniel Buchanan
Daniel Buchanan
MCMark Clendenning
Mark Clendenning
CRChristophe Rosty
Christophe Rosty
SEStine V Eriksen
Stine V Eriksen
MWMichael D Walsh
Michael D Walsh
MJMark A Jenkins
Mark A Jenkins